Structured evidence table for Glucosamine Knee Discomfort Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Glucosamine Knee Discomfort Randomized Trial | This review suggests that EAS may be an effective and relatively safe adjunctive option for KOA; however, the certainty of the evidence is low due to substantial heterogeneity and potential biases. | 1 | Yang G (2025) | The efficacy and safety of electrical acupoint stimulation (EAS) for knee osteoarthritis (KOA): A GRADE-assessed systematic review, meta-analysis and trial sequential analysis. |
| Glucosamine Knee Discomfort Randomized Trial | Electrical acupoint stimulation (EAS) is proposed as a potentially beneficial treatment for patients suffering from knee osteoarthritis (KOA). | 1 | Yang G (2025) | The efficacy and safety of electrical acupoint stimulation (EAS) for knee osteoarthritis (KOA): A GRADE-assessed systematic review, meta-analysis and trial sequential analysis. |
| Glucosamine Knee Discomfort Randomized Trial | This systematic review and meta-analysis aims to assess the assess the effectiveness and safety of EAS for KOA. | 1 | Yang G (2025) | The efficacy and safety of electrical acupoint stimulation (EAS) for knee osteoarthritis (KOA): A GRADE-assessed systematic review, meta-analysis and trial sequential analysis. |
| Glucosamine Knee Discomfort Randomized Trial | , , d d N Figure Chondroitin sulfate (CS) is an anionic, sulfated glycosaminoglycan found in various connective tissues, including cartilage, bone, ligaments, tendons, and skin. | 3 | Silva Vitor Alfredo de Santana (2025) | Impact of Symptomatic Slow-Acting Drugs on Inflammatory Pathways in Osteoarthritis: Therapeutic Advances and Future Challenges |
| Glucosamine Knee Discomfort Randomized Trial | In terrestrial animals, it is predominantly found as monosulfated disaccharides at the 4-O or 6-O positions of GalNAc (CS-A and CS-C, respectively), along with a small percentage of nonsulfated disaccharides (CS-0). | 3 | Silva Vitor Alfredo de Santana (2025) | Impact of Symptomatic Slow-Acting Drugs on Inflammatory Pathways in Osteoarthritis: Therapeutic Advances and Future Challenges |
| Glucosamine Knee Discomfort Randomized Trial | While foundational and pioneering studies are acknowledged, particular emphasis is placed on the most recent evidence to capture the current state of knowledge, clarify ongoing controversies, and highlight the latest therapeutic advances. | 3 | Silva Vitor Alfredo de Santana (2025) | Impact of Symptomatic Slow-Acting Drugs on Inflammatory Pathways in Osteoarthritis: Therapeutic Advances and Future Challenges |
| Glucosamine Knee Discomfort Randomized Trial | Osteoarthritis (OA) is a highly prevalent musculoskeletal rheumatic disorder that significantly impacts individual health, healthcare systems, and overall socioeconomic costs.OA remains a substantial global health burden: in 2020, an estimated 595 million people (≈7.6% of the global population) had OA, representing a 132.2% increase in cases since 1990. | 3 | Silva Vitor Alfredo de Santana (2025) | Impact of Symptomatic Slow-Acting Drugs on Inflammatory Pathways in Osteoarthritis: Therapeutic Advances and Future Challenges |
Source documents